Exelixis Inc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Exelixis Inc (EXEL) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $1.60 billion as of 2019-09-27, per its 10-Q filed 2019-10-30.
Discontinued › Balance Sheet
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2019-10-30
- 2019-09-27: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.60B.
- 2019-06-28: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.49B.
- 2019-03-29: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.39B.
- 2018-12-28: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.29B.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2019-09-27 | $1.60B 10-Q · filed 2019-10-30 | |
| 2019-06-28 | $1.49B 10-Q · filed 2019-10-30 | |
| 2019-03-29 | $1.39B 10-Q · filed 2019-07-31 | |
| 2018-12-28 | $1.29B 10-Q · filed 2019-10-30 | |
| 2018-09-28 | $915.97M 10-Q · filed 2019-10-30 | |
| 2018-06-29 | $775.20M 10-Q · filed 2019-10-30 | $774.97M 10-Q · filed 2018-08-01 |
| 2018-03-30 | $670.00M 10-Q · filed 2019-07-31 | $669.77M 10-Q · filed 2018-05-02 |
| 2017-12-29 | $284.96M 10-Q · filed 2019-10-30 | |
| 2017-09-30 | $238.72M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $148.51M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $119.75M 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $89.32M 10-Q · filed 2017-11-01 | |
| 2016-12-30 | $89.32M 10-K · filed 2019-02-22 | |
| 2016-09-30 | $32.02M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$186.13M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | -$155.95M 10-Q · filed 2016-05-04 | |
| 2016-01-01 | -$140.81M 10-K · filed 2019-02-22 | |
| 2015-12-31 | -$140.81M 10-K · filed 2017-02-27 | -$104.30M 10-K · filed 2016-02-29 |
| 2015-09-30 | -$74.23M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | -$188.19M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | -$146.76M 10-Q · filed 2015-04-30 | |
| 2015-01-02 | -$159.32M 10-K · filed 2018-02-26 | |
| 2014-12-31 | -$159.32M 10-K · filed 2017-02-27 | -$114.83M 10-K · filed 2015-03-02 |
| 2014-09-30 | -$58.51M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $3.24M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $71.48M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $14.50M 10-K · filed 2017-02-27 | $66.24M 10-K · filed 2014-02-20 |
| 2013-09-30 | $132.76M 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $196.33M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $254.85M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $238.13M 10-K · filed 2017-02-27 | $296.43M 10-K · filed 2013-02-21 |
| 2012-09-30 | $340.85M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $99.05M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $132.35M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $90.63M 10-K · filed 2015-03-02 | |
| 2011-09-30 | $3.05M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | -$81.81M 10-Q · filed 2011-08-04 | |
| 2010-12-31 | -$228.32M 10-K · filed 2014-02-20 | |
| 2009-12-31 | -$163.72M 10-K · filed 2013-02-21 | |
| 2008-12-31 | -$56.26M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |